Table 1

Baseline demographics

OCTAVE induction 1
(n=475)
Sample of UC cohort
(n=28)
Male sex, n (%)277 (58.2)16 (57)
Age, years41.3±14.143.2±14.4
Duration of disease, years
 Median6.510.2
 Range0.3–42.52.2–51.4
Extent of disease, n/total n (%)
 Proctosigmoiditis64/475 (13.7)3/28 (10.7)
 Left-sided colitis158/475 (33.3)6/28 (21.4)
 Extensive colitis/pancolitis252/475 (53.1)19/28 (67.9)
Total Mayo score9.0±1.48.5±1.8
Partial Mayo score6.3±1.26±1.6
CRP, mg/L
 Median4.45.8
 Range0.1–208.40.8–70.6
Glucocorticoid use at baseline*214 (45.0)17 (60.7)
Previous treatment with TNF inhibitor, n (%)254 (53.4)28 (100)
Previous treatment failure, n (%)
 TNF inhibitor243 (51.1)28 (100)
 Glucocorticoid350 (73.5)24 (85.7)
 Immunosuppressant360 (75.6)21 (75)
Panés et al9
(n=86)
Sample of CD cohort
(n=13)
Female, n (%)47 (54.7)9 (69.2)
Age, years
 Mean (SD)39.3 (13.7)39.7 (19.5)
Weight, kg
 Mean (SD)71.6 (18.8)69.9 (16.3)
Race, n (%)
 White72 (83.7)9 (69.2)
 Black2 (2.3)0 (0)
 Asian11 (12.8)1 (7.7)
 Others1 (1.2)0 (0)
Duration since CD diagnosis, years
 Mean (SD)11.3 (9.7)14.4 (8.2)
Extent of disease, n (%)
 L1 (Ileal)7 (8.1)1 (7.7)
 L1/4 (Ileal + Upper GI)2 (2.3)2 (15.4)
 L2 (Colonic)5 (5.8)0 (0)
 L2/4 (Colonic + Upper GI)16 (18.6)1 (7.7)
 L3 (Ileocolonic)15 (17.4)4 (30.8)
 L3/4 (Ileocolonic)39 (45.3)5 (38.5)
Prior use of TNF inhibitor, n (%)66 (76.7)13 (100)
Use of corticosteroids at study entry, n (%)28 (32.6)7 (53.8)
Baseline CDAI score
 Mean (SD)320 (61.66)374 (183.73)
Baseline CRP, mg/L
 Median (min-max)5.5 (0.2–126)28.7 (3.5–107)
  • Within each pair of columns, the left columns corresponds to the patient demographics of the tofacitinib-assigned arm in corresponding RCTs (eg, the OCTAVE trials reported by Sandborn et al, the CD trials reported by Panés et al). The right columns reports the corresponding demographics of a sample of tofacitinib-treated patients at UCSF. Treatment failure is defined as an inadequate response to any treatment (eg, steroids, TNF inhibitor) as defined and documented by the treating clinician.

  • CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; RCTs, randomised controlled trials; TNF, tumour necrosis factor; UCSF, University of California, San Francisco.